Auxilium sells $325m in convertible debt to fund hedges and operations
This article was originally published in Scrip
Executive Summary
Auxilium Pharmaceuticals is selling 1.5% convertible senior notes due in 2018 with an aggregate principal amount of $325 million for "general corporate purposes" and to pay the cost of note hedge transactions meant to protect investors from dilution and offset the company's cash payments associated with selling debt to finance its operations.